
JustForFun ( Date: 16-Apr-2011 12:09) Posted:
|
results  out last week of May for the last couple of years.....the 27/4  u mentioned was  the notification of when the results will be released.
result out in last year was mid of last week of april.
around 27/4,so in 10 day time ,we will know.
at meantime it will move higher .
rogeryap ( Date: 15-Apr-2011 23:00) Posted:
|
strong support at 1.33 ,so it should be good for run to 1.38 by mid next week
guess u r rite to take profits off the table..no one can predict the highest price unless u r INSIDE...
Sold most of my holdings. With the rise from 1.10 to 1.34 today. It is time for a correction - will come back again when it corrected to between  1.25-1.27
Arguably a rising wedge is forming if we take the  peak on   March 9 as part of the upper resistance line. Rising wedges are one of a sure sign of reversals. Good luck folks.
Are we in an  ascending triangle forming?
Good observation ``Investor`.   I still cannot fathom out the reason for their(FDL) recent sales and the quick  repurchase??. May be they know something good coming that we don`t know. You described the recent uptrend as slight but I see as  quite ``explosive`` which is probably intiated by the  Nobori stent approval in Japan and the recent  recruitment of the new talented CFO.  Most of the members of the senior management of BIG are now Asian and such move indicate that BIG are switching their focus into China now. Great transformation  is coming , I believe.       
investor ( Date: 14-Apr-2011 16:52) Posted:
|
TODAY VOLUME AT 21,016,000 SHARE
18,000,000OF   SHARE BUY IN  AT 1.30.
AT THIS   SUPPORT ,IT SHOULD BREAK 1.31 BY NEXT DAY EASY.
1.30 will be hard to cross. May have to pull back before going higher.
 
A lot of people may not have noticed this. When Fidelity sold their shares on 30th Mar, the number of shares that they hold after the sale was 54.921 million.
In today's announcement, before the new purchase on 8th Apr, the number of shares that they own is 65.729 million. That is between 31st Mar to 7th Apr, they actually increase the number of shares by 10.808 million, without the need to report, as the total number of shares in Biosensors has increased, due to the new shares issued to the 2 new shareholders, and hence they have not breach the 5 % limit.
That could be the reason, why the shares have been on a slight uptrend recently.
Not a call to buy/sell.
Interesting...... they(FID) had just recently reduced their stake in BIG last month to just below 5% ( check company announcement in SGX March 2011) and now they may have realised it is a  mistake to sell and decided to buy back again.
BIG potentially can go up to $1.50 soon as the new CFO  has very good tract record in M& A and this augur well for BIG next strategic development.Sit tight for M& A and good news.     
allright ( Date: 14-Apr-2011 15:27) Posted:
|
NOTICE OF  A SUBSTANTIAL SHAREHOLDER'S INTEREST  * |
* Asterisks denote mandatory information |
Name of Announcer * | BIOSENSORS INT'L GROUP, LTD.   |
Company Registration No. | EC 24983   |
Announcement submitted on behalf of | BIOSENSORS INT'L GROUP, LTD.   |
Announcement is submitted with respect to * | BIOSENSORS INT'L GROUP, LTD.   |
Announcement is submitted by * | YOH-CHIE LU   |
Designation * | CHAIRMAN   |
Date & Time of Broadcast | 14-Apr-2011 12:34:26   |
Announcement No. | 00027   |
> > ANNOUNCEMENT DETAILS |
The details of the announcement start here ... |
> > PART I |
1. | Date of notice to issuer * | 14-04-2011   |
2. | Name of  Substantial Shareholder  * | (1) FMR LLC (2) FIL Limited and (3) Edward C. Johnson 3d  |
3. | Please tick one or more appropriate box(es): * |
  |
> > PART II |
1. | Date of change of  Deemed Interest | 08-04-2011   |
2. | Name of Registered Holder | Please see below footnote   |
3. | Circumstance(s) giving rise to the interest or change in interest | Open Market Purchase   | |
  | # Please specify details |
|
4. | Information relating to shares held in the name of the Registered Holder | ||||||||||||||
  |
 
 
 
|
> > PART III |
1. | Date of change of  [Select Option] |   |
2. | The change in the percentage level | From % To % |
3. | Circumstance(s) giving rise to the interest or change in interest | [Select Option]   | |
  | # Please specify details |
|
4. | A statement of whether the change in the percentage level is the result of a transaction or a series of transactions: |
|
> > PART IV |
1. | Holdings of  Substantial Shareholder  , including direct and deemed interest : |
![]() | Direct | Deemed |
No. of shares held before the change | 0   | 65,729,000   |
As a percentage of issued share capital | 0 % | 4.92 % |
No. of shares held after the change | 0   | 66,979,000   |
As a percentage of issued share capital | 0 % | 5.02 % |
Footnotes |
|
Attachments | Total size =  0 (2048K size limit recommended) |
Nobori stent approved in Japan
Nobori stent approved for sale in Japan…
International Group (BIG) announced that Terumo Corporation
(Terumo) has received approval for the sale of its Nobori drugeluting
stent (DES) in Japan, based on a document released
by Japan's Ministry of Health, Labour and Welfare. The Nobori
DES uses the stent technology and proprietary Biolimus A9
drug licensed from BIG (similar to BIG's BioMatrix DES) in
exchange for royalty payments. Currently, BIG already enjoys
a stream of licensing and royalties revenue from Terumo for
its Nobori DES which is sold outside of Japan and U.S. We
note that Terumo had entered into a revised licensing agreement
with BIG in Apr 2008, whereby it agreed to pay BIG US$40m
in exchange for a reduction of the revenue sharing provisions
applicable to sales of the Nobori DES outside of Japan. This
suggests Terumo's optimism about the growth prospects of
the DES market as well as its ability to increase its penetration
rates, in our opinion.
Biosensors…means higher licensing revenue for BIG
has not announced or rolled out its plans for the launch of its
Nobori DES in Japan, we estimate that this should happen
sometime in the early part of FY12. Hence BIG would be able
to reap higher licensing revenues from Terumo when this
happens. The DES market for Japan is estimated to be worth
~US$600m and is currently dominated by the four U.S.
medical technology giants. We believe this is now likely to
change after Nobori's approval in Japan. Strong penetration in
the Japanese market would be underpinned by (i) the proven
safety and efficacy of BIG's DES technology and (ii) Terumo's
ability to leverage on Japanese physicians’ loyalty given that
it is the first local firm to rollout a DES.
. While TerumoAppointment of new CFO
hired Mr. Ronald Ede as its new CFO. Mr. Ede was formerly
the CFO of Mindray Medical International, the largest medical
equipment company in China which trades on NYSE. BIG
believes that Mr. Ede's expertise in the M& A area would be
invaluable in the group's future development as inorganic
growth is expected to play a key role in its expansion plans.
. BIG also announced that it hasReiterate BUY.
catalyst for growth following the approval of Nobori's sale in
Japan. We update our assumptions for BIG's licensing
revenues and bump up our FY12F revenue and core earnings
forecasts by 7.3% and 10.6% respectively. This in turn raises
our DCF-based fair value estimate from S$1.32 to S$1.48.
Biosensors International Group's Key Financial Data
EARNINGS FORECAST BALANCE SHEET
Year Ended 31 Mar (US$m) FY09 FY10 FY11F FY12F As at 31 Mar (US$m) FY09 FY10 FY11F FY12F Revenue 119.0 116.2 157.9 229.7 Bank and cash balances 60.1 60.1 277.7 312.5
EBITDA 19.1 24.6 45.9 70.9 Other current assets 37.7 51.1 59.7 84.3
Depreciation and amortisation 2.9 2.7 2.8 2.7 Property, plant, and equipment 9.9 9.7 9.5 9.3
EBIT 16.2 22.0 43.2 68.2 Total assets 198.5 227.8 472.8 555.1
Net interests -2.8 -3.8 -5.0 -4.9 Debt 46.8 29.1 31.3 33.4
Share of results of JVs, net 7.3 14.9 19.0 23.1 Current liabilities excluding debt 45.4 51.0 53.3 57.5
Profit before tax 8.9 33.7 46.3 86.4 Total liabilities 94.6 83.1 87.5 93.8
Income tax expense -10.0 -1.6 -6.5 -10.4 Shareholders equity 103.9 144.7 385.3 461.3
Minority interests 0.0 0.0 0.0 0.0 Minority interests 0.0 0.0 0.0 0.0
Profit attributable to shareholders -1.1 32.1 39.8 76.0 Total equity and liabilities 198.5 227.8 472.8 555.1 CASH FLOW
Year Ended 31 Mar (US$m) FY09 FY10 FY11F FY12F Op profit before working cap. chg. 29.0 34.9 35.0 70.9 EPS (US cents) -0.1 3.0 3.5 5.8
Working cap, taxes and int -18.0 -22.1 -17.8 -35.7 NTA per share (US cents) 8.7 12.3 28.1 33.9
Net cash from operations 11.0 12.8 17.2 35.2 EBIT margin (%) 13.6 18.9 27.3 29.7
Purchase of PP& E -5.1 -2.1 -2.5 -2.5 Net profit margin (%) -0.9 27.6 25.2 33.1
Other investing flows -0.4 0.0 0.0 0.0 PER (x) n.m. 3 2.8 2 8.7 17.0
Investing cash flow -5.5 -2.2 -2.5 -2.5 Price/NTA (x) 1 1.4 8.1 3 .5 2.9
Financing cash flow 0.3 -10.7 203.0 2.1 EV/EBITDA (x) 6 7.9 5 2.0 2 3.2 14.6
Net cash flow 5.8 0.0 217.7 34.7 Dividend yield (%) 0.0 0.0 0.0 0.0
Cash at beginning of year 54.3 60.1 60.1 277.7 ROE (%) -1.1 25.8 15.0 18.0
Reiterate
Cash at end of year 60.1 60.1 277.7 312.5 Net gearing (%) net cash net cash net cash net cash